Page last updated: 2024-11-06

ibuproxam

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ibuproxam: RN given refers to cpd without isomeric designation; structure in Negwer, 5th ed, #6312 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ibuproxam : A hydroxamic acid obtained by formal condensation of the carboxy group of ibuprofen with the amino group of hydroxylamine. Used for treatment of pain and inflammation associated with musculoskeletal and joint disorders. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID68704
CHEMBL ID292707
CHEBI ID76160
SCHEMBL ID24896
MeSH IDM0084635

Synonyms (44)

Synonym
g-277
nsc305528
53648-05-8
nsc-305528
ibuproxam
ibudros
ibuproxam (inn)
D07268
ibudros (tn)
CHEMBL292707 ,
chebi:76160 ,
n-hydroxy-2-[4-(2-methylpropyl)phenyl]propanamide
n-hydroxy-2-(4-isobutylphenyl)propanamide
n-hydroxy-2-(4-isobutyl-phenyl)-propionamide
bdbm50012894
AKOS005356866
mfcd00866059
einecs 258-683-8
o3ld16o96z ,
2-(4-isobutylphenyl)propionohydroxamsaeure
ibuproxamum
nsc 305528
n-hydroxy-2-(4-isobutylphenyl)propionamid
ibuproxam [inn]
g 277
p-isobutylhydratropohydroxamic acid
ibuproxamum [inn-latin]
deflogon
benzeneacetamide, n-hydroxy-alpha-methyl-4-(2-methylpropyl)-
unii-o3ld16o96z
ibuproxam [mi]
ibuproxam [who-dd]
ibuproxam [mart.]
CCG-207960
smr004701788
MLS006010859
SCHEMBL24896
DB08955
Q3791611
DTXSID30866353
BRD-A40940854-001-01-1
g 277; ibudros
CS-0009221
HY-17486

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Despite their potent enzyme inhibitory activity in vitro, many orally dosed hydroxamic acids only weakly inhibited leukotriene synthesis in vivo."( In vivo characterization of hydroxamic acid inhibitors of 5-lipoxygenase.
Bouska, JB; Brooks, DW; Carter, GW; Dyer, RD; Goetze, AM; Gunn, BP; Mazdiyasni, H; Summers, JB; Young, PR, 1987
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
non-steroidal anti-inflammatory drugAn anti-inflammatory drug that is not a steroid. In addition to anti-inflammatory actions, non-steroidal anti-inflammatory drugs have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins.
iron chelatornull
non-narcotic analgesicA drug that has principally analgesic, antipyretic and anti-inflammatory actions. Non-narcotic analgesics do not bind to opioid receptors.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
hydroxamic acidA compound, RkE(=O)lNHOH, derived from an oxoacid RkE(=O)l(OH) (l =/= 0) by replacing -OH with -NHOH, and derivatives thereof. Specific examples of hydroxamic acids are preferably named as N-hydroxy amides.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Polyunsaturated fatty acid 5-lipoxygenaseRattus norvegicus (Norway rat)IC50 (µMol)19.06220.00462.018210.0000AID6856; AID6860; AID7184; AID7185
Prostaglandin G/H synthase 2 Rattus norvegicus (Norway rat)IC50 (µMol)10.00000.00291.786810.0000AID161005
Prostaglandin G/H synthase 1 Rattus norvegicus (Norway rat)IC50 (µMol)10.00000.00291.823210.0000AID161005
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID174496Plasma concentration was evaluated for corresponding hydroxamic acid metabolite at 100 mg/kg dose peroral administration in rats after 60 min1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
In vivo characterization of hydroxamic acid inhibitors of 5-lipoxygenase.
AID174494Plasma concentration was evaluated for corresponding hydroxamic acid metabolite at 100 mg/kg dose peroral administration in rats after 20 min1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
In vivo characterization of hydroxamic acid inhibitors of 5-lipoxygenase.
AID7184In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1)1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships.
AID440476Half life in rat at 100 mg/kg, po2009Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21
Hydroxamates: relationships between structure and plasma stability.
AID6860Inhibition of 5-lipoxygenase in intact RBL-1 cell line1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Nonsteroidal antiinflammatory drug hydroxamic acids. Dual inhibitors of both cyclooxygenase and 5-lipoxygenase.
AID174490Plasma concentration was evaluated for corresponding carboxylic acid metabolite at 100 mg/kg dose peroral administration in rats after 20 min1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
In vivo characterization of hydroxamic acid inhibitors of 5-lipoxygenase.
AID592681Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
QSAR-based permeability model for drug-like compounds.
AID183255Inhibition of leukotriene biosynthesis was determined in vivo with the rat peritoneal anaphylaxis model administered perorally at 100 mg/kg; not significant1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
In vivo characterization of hydroxamic acid inhibitors of 5-lipoxygenase.
AID7185Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1)1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships.
AID161005Inhibition of Prostaglandin G/H synthase in intact RBL-1 cell line1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Nonsteroidal antiinflammatory drug hydroxamic acids. Dual inhibitors of both cyclooxygenase and 5-lipoxygenase.
AID174492Plasma concentration was evaluated for corresponding carboxylic acid metabolite at 100 mg/kg dose peroral administration in rats after 60 min1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
In vivo characterization of hydroxamic acid inhibitors of 5-lipoxygenase.
AID227084Relative binding affinity to 5-lipoxygenase and cyclooxygenase1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Nonsteroidal antiinflammatory drug hydroxamic acids. Dual inhibitors of both cyclooxygenase and 5-lipoxygenase.
AID6856In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
In vivo characterization of hydroxamic acid inhibitors of 5-lipoxygenase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (36.84)18.7374
1990's8 (42.11)18.2507
2000's3 (15.79)29.6817
2010's1 (5.26)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.56 (24.57)
Research Supply Index3.00 (2.92)
Research Growth Index4.22 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (24.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies4 (21.05%)4.05%
Observational0 (0.00%)0.25%
Other15 (78.95%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]